Figure 1. Prophylactic vaccination against B16-OVA/.

C57BL/6J (WT) and FtDKO mice were vaccinated intravenously with LM-OVA and challenged with B16-OVA subcutaneously (A) 21 days, (B) 93 days or (C) 126 days post-infection. Survival curves were based on animals reaching a tumor size, 200 mm². (D), Mice were challenged intravenously with B16-OVA, 21 days post LM-OVA infection. Survival was based on animals exhibiting a maximum weight loss of 20% or other clinical signs of illness. (E), Lung metastatic foci enumerated on day 15 post-tumor challenge in representative mice. Similar trend was noted for n = 5 mice/group. Significant differences were observed in panel A (p = 0.0082), panel B (p = 0.0015) and panel c (p = 0.03) by log-rank test.